
A global trial (STEP-HFpEF DM) found that weekly semaglutide 2.4 mg significantly improved heart failure symptoms, physical limitations, and bodyweight in obese patients with type 2 diabetes, regardless of baseline HbA1c. Conducted across 16 countries, the study confirmed semaglutide's benefits with lower hypoglycemia risk compared to placebo, highlighting its potential in HFpEF management.
Like
Save
Share